Alterity Therapeutics (PBN) Stock Overview

Engages in research and development of Parkinsonian and neurodegenerative disorders, including Multiple System Atrophy (MSA) and Parkinson’s disease. More details

PBN fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	2/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

Rewards

Revenue is forecast to grow 63.97% per year

Risk Analysis

Highly volatile share price over the past 3 months compared to the German market

Shareholders have been diluted in the past year

Does not have meaningful revenue (A$4M)

Currently unprofitable and not forecast to become profitable over the next 3 years

+ 1 more risk

PBN Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW436,082 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.

Grow your followingReal investors. The kind who actually invest, not scroll past.

Unlock free accessFree premium subscription for consistent and quality authors.

Learn more Create Narrative

436,082 investors already sharing narratives

View all narratives

Alterity Therapeutics Limited Competitors

Price History & Performance

Summary of share price highs, lows and changes for Alterity Therapeutics
Historical stock prices
Current Share Price	AU$0.30
52 Week High	AU$0.45
52 Week Low	AU$0.10
Beta	-0.043
1 Month Change	-5.10%
3 Month Change	49.00%
1 Year Change	8.36%
3 Year Change	198.00%
5 Year Change	-55.85%
Change since IPO	-92.26%

Recent updates

Shareholder Returns

	PBN	DE Biotechs	DE Market
7D	-1.3%	-3.6%	-0.5%
1Y	8.4%	-7.7%	4.6%

Return vs Industry: PBN exceeded the German Biotechs industry which returned -6.9% over the past year.

Return vs Market: PBN exceeded the German Market which returned 5.5% over the past year.

Price Volatility

Is PBN's price volatile compared to industry and market?
PBN volatility
PBN Average Weekly Movement	18.3%
Biotechs Industry Average Movement	5.5%
Market Average Movement	5.0%
10% most volatile stocks in DE Market	12.4%
10% least volatile stocks in DE Market	2.5%

Stable Share Price: PBN's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: PBN's weekly volatility has decreased from 37% to 18% over the past year, but is still higher than 75% of German stocks.

About the Company

Founded	Employees	CEO	Website
1997	11	David Stamler	alteritytherapeutics.com

Alterity Therapeutics Limited is engages in research and development of Parkinsonian and neurodegenerative disorders, including Multiple System Atrophy (MSA) and Parkinson’s disease. The company’s lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase II clinical trial for the treatment of Parkinson’s disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; and ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy, as well as bioMUSE, biomarkers of progression in multiple system atrophy.

Alterity Therapeutics Limited Fundamentals Summary

How do Alterity Therapeutics's earnings and revenue compare to its market cap?
PBN fundamental statistics
Market cap	€68.47m
Earnings (TTM)	-€14.52m
Revenue (TTM)	€2.24m

30.6x

P/S Ratio

-4.7x

P/E Ratio

Is PBN overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
PBN income statement (TTM)
Revenue	AU$3.61m
Cost of Revenue	AU$262.78k
Gross Profit	AU$3.35m
Other Expenses	AU$26.75m
Earnings	-AU$23.40m

Last Reported Earnings

Jun 30, 2026

Next Earnings Date

n/a

Earnings per share (EPS)	-0.11
Gross Margin	92.72%
Net Profit Margin	-648.22%
Debt/Equity Ratio	0%

How did PBN perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/09/09 13:07
End of Day Share Price	2026/09/09 00:00
Earnings	2026/06/30
Annual Earnings	2026/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Alterity Therapeutics Limited is covered by 8 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
George Zavoico	B. Riley Securities, Inc.
Madeleine Williams	Canaccord Genuity
Adam Vogel	Craig-Hallum Capital Group LLC

Alterity Therapeutics (PBN) Stock Overview

Rewards

Risk Analysis

Join community and earn perks

Alterity Therapeutics Limited Competitors

Genetic Analysis

2invest

Heidelberg Pharma

Novogenia

Price History & Performance

Recent News & Updates

Alterity Therapeutics Announces Granting Of New U.S. Composition Of Matter Patent For ATH434

Alterity Therapeutics Limited Receives FDA End-Of-Phase 2 Meeting Minutes Confirming Registrational Pathway For ATH434 In Multiple System Atrophy

New major risk - Market cap size

Alterity Therapeutics Announces Data Presentations Supporting Advancement Of ATH434 Into Phase 3 In Multiple System Atrophy

Less than half of directors are independent

Alterity Therapeutics Announces Utility of Quantitative Mri as Biomarker for Multiple System Atrophy

Recent updates

Alterity Therapeutics Announces Granting Of New U.S. Composition Of Matter Patent For ATH434

Alterity Therapeutics Limited Receives FDA End-Of-Phase 2 Meeting Minutes Confirming Registrational Pathway For ATH434 In Multiple System Atrophy

New major risk - Market cap size

Alterity Therapeutics Announces Data Presentations Supporting Advancement Of ATH434 Into Phase 3 In Multiple System Atrophy

Less than half of directors are independent

Alterity Therapeutics Announces Utility of Quantitative Mri as Biomarker for Multiple System Atrophy

Alterity Therapeutics Receives Positive FDA Feedback on Ath434 Phase 3 Program in Multiple System Atrophy

Alterity Therapeutics Presents New Analysis of ATH434 Phase 2 Trial Data in Late Breaking Science Session of the American Academy of Neurology

Alterity Therapeutics Limited Appoints Ann Cunningham as Independent Non-Executive Director, Effective April 17, 2026

Alterity Therapeutics Limited Receives Positive FDA Feedback on Ath434 Phase 3 Program

Alterity Therapeutics Limited Appoints Daniel O. Claassen, M.D., M.S., as Chief Medical Advisor, Effective March 2026

Alterity Therapeutics Limited Recognizes Multiple System Atrophy (MSA) Awareness Month in March and the Urgent Need for Disease-Modifying Treatments

Alterity Therapeutics Presents Promising Impact of Ath434 on Orthostatic Hypotension and Disease Progression in Msa At the 36Th International Symposium on the Autonomic Nervous System

Alterity Therapeutics Presents Positive Data from ATH434 Phase 2 Trial At the 2025 International Congress of Parkinson's Disease and Movement Disorders

Alterity Therapeutics to Deliver Multiple Presentations at the 2025 International Congress of Parkinson's Disease and Movement Disorders

Alterity Therapeutics Limited, Annual General Meeting, Nov 21, 2025

Alterity Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 20 million.

Alterity Therapeutics Reports Positive Topline Data from Open-Label Phase 2 Clinical Trial of ATH434 in Multiple System Atrophy

Alterity Therapeutics Announces Publication on Novel MRI Endpoint from the BioMUSE Natural History Study

Alterity Therapeutics Limited Prominently Featured at the International MSA Congress

Alterity Therapeutics Grants U.S. FDA Fast Track Designation for ATH434 to Treat Multiple System Atrophy

Alterity Therapeutics Presents ATH434-201 Phase 2 Clinical Trial Results at European MSA Symposium

Alterity Therapeutics Presents Encouraging New Data from Its Ath434 Phase 2 Trial in Multiple System Atrophy At the American Academy of Neurology Annual Meeting

Alterity Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 40 million.

Alterity Therapeutics Limited Completes Last Patient Visit in Open-Label Trial

Alterity Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 40.7 million.

Alterity Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 2.118724 million.

Alterity Therapeutics Announces Positive ATH434 Phase 2 Trial Results in Multiple System Atrophy Led by Robust Clinical Efficacy

Insufficient new directors

Alterity Therapeutics Completes Last Patient Visit in ATH434-201 Phase 2 Clinical Trial in Early-Stage Multiple System Atrophy

Alterity Therapeutics Limited Announces Management Changes

Alterity Therapeutics Limited Announces Presentation on Tracking the Progression of Multiple System Atrophy at International Symposium

Alterity Therapeutics Announces New Publication Describing Novel Mechanism of Action for ATH434

Alterity Therapeutics Limited, Annual General Meeting, Nov 22, 2024

Alterity Therapeutics Limited Announces Chief Financial Officer Changes

Alterity Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 0.406192 million.

Alterity Therapeutics Limited Reports Positive Interim Data from ATH434-202 Phase 2 Clinical Trial in Multiple System Atrophy

Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Third Review

Alterity Therapeutics Limited Presents New Data Demonstrating Potential of ATH434 to Treat Rare Neurodegenerative Diseases

Alterity Therapeutics Limited has filed a Follow-on Equity Offering in the amount of $6 million.

Alterity Therapeutics's Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Second Review

Alterity Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 4.8 million.

Alterity Therapeutics Limited Announces CFO Changes

Alterity Therapeutics Reports Positive Efficacy Data for ATH434 in a Primate Model of Parkinson's Disease

New minor risk - Shareholder dilution

Alterity Therapeutics Announces Presentation of Novel Biomarker Data for Evaluation of Multiple System Atrophy

Alterity Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 2 million.

Alterity Therapeutics Completes Enrolment in Ath434-201 Phase 2 Clinical Trial in Multiple System Atrophy

New major risk - Market cap size

Alterity Therapeutics Limited, Annual General Meeting, Nov 29, 2023

New minor risk - Financial data availability

Alterity Therapeutics Limited Grants New Composition of Matter Patent in Europe for Neurodegenerative Diseases Including Parkinson's and Alzheimer's

Alterity Therapeutics Limited Announces an Independent Data Monitoring Committee Recommends the ATH434-201 Phase 2 Study

Alterity Therapeutics Initiates Second Phase 2 Study in Rare Parkinsonian Disorder

Alterity Therapeutics Enrolls First Patient in Australia in Ath434 Global Phase 2 Clinical Trial in Multiple System Atrophy

Alterity Therapeutics Limited Receives Regulatory Approval for Phase II Trial in France and Austria

Alterity Therapeutics Limited Announces A Study Recently Published in the Journal Neurotherapeutics Demonstrated Its Lead Clinical Asset, Ath34, Was Neuroprotective in A Genetic Model of Parkinson's Disease

Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial in Italy for the Treatment of Individuals with Multiple System Atrophy

Alterity Therapeutics Limited Launches ATH434 Phase 2 Clinical Trial in the United States for the Treatment of Individuals with Multiple System Atrophy

Insufficient new directors

Insufficient new directors

Shareholder Returns